[EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2017044434A1
公开(公告)日:2017-03-16
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
申请人:Li Hui
公开号:US20100190770A1
公开(公告)日:2010-07-29
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Photoinduced C(sp<sup>3</sup>)–H sulfination empowers the direct and chemoselective introduction of the sulfonyl group
作者:Shengfei Jin、Graham C. Haug、Ramon Trevino、Viet D. Nguyen、Hadi D. Arman、Oleg V. Larionov
DOI:10.1039/d1sc04245a
日期:——
aliphatic C–H bonds to sulfinates has remained elusive, due to the reactivity of sulfinates that are incompatible with typical oxidation-driven C–H functionalization approaches. We report herein a photoinduced C(sp3)–H sulfination reaction that is mediated by sodium metabisulfite and enables access to a variety of sulfinates. The reaction proceeds with high chemoselectivity and moderate to good regioselectivity
[EN] PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES DE PHENYLALANINE-ENAMIDE
申请人:CELLTECH R&D LTD
公开号:WO2004007428A1
公开(公告)日:2004-01-22
A process for the preparation of a class of phenylalanine enamide derivatives is described formula (1) wherein: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a linker group selected from -N(R4)- [where R4 is a hydrogen atom or an optionally substituted straight or branched C1-6alkyl group], -CON(R4)-, or -S(O)2N(R4)-; R1 is a carboxylic acid (-CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Rx, Ry and Rz which may be the same or different is each an atom or group -L1(Alk1)n(R3)v; and the salts, solvates, hydrates and N-oxides thereof; which comprises reacting a compound of formula (2): wherein: Qa is a group -N(R4)H; and the salts, solvates, hydrates and N-oxides thereof; with a compound Ar1W wherein W is a group selected from X1 (wherein X1 is a leaving atom or group), -COX2 (wherein X2 is a halogen atom or a -OH group) or -SO2 X3 (in which X3 is a halogen atom).
Enamine derivatives of formula (1) are described:
1
wherein
R
1
is a group Ar
1
L
2
Ar
2
Alk- in which Ar
1
is an aromatic or heteroaromatic group, L
2
is a covalent bond or a linker atom or group, Ar
2
is an arylene or heteroarylene group and Alk is a chain —CH
2
—CH(R)—, —CH═C(R)— or
2
in which R is a carboxylic acid or a derivative or biostere thereof;
R
2
is a hydrogen atom or a C
1-6
alkyl group;
Cy is a cycloaliphatic or heterocycloaliphatic ring in which X is a N atom or a C(R
w
) group;
R
x
is a oxo, thioxo, or imino group;
R
w
and R
z
is each a hydrogen atom or optional substituent;
provided that Cy is not a cyclobutenedione group;
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.